Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study
- 249 Downloads
Background Increased adiposity is thought to result in worse clinical outcomes in patients with breast cancer through increased estrogen production, hyperinsulinemia, insulin resistance, and activation of the phosphatidylinositol-3-kinase/AKT/mammalian target of rapamycin (mTOR) pathway. Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer. We conducted a phase II trial to evaluate the efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal women with metastatic, hormone receptor-positive, HER2-negative breast cancer. Methods Twenty-two patients with a body mass index ≥25 kg/m2 were treated with metformin 1000 mg twice daily, everolimus 10 mg daily and exemestane 25 mg daily. Median progression-free (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Results Median PFS and OS were 6.3 months (95% confidence interval [CI]: 3.8–11.3 months) and 28.8 months (95% CI: 17.5–59.7 months), respectively. Five patients had a partial response and 7 had stable disease for ≥24 weeks yielding a clinical benefit rate of 54.5%. Compared with overweight patients, obese patients had an improved PFS on univariable (p = 0.015) but not multivariable analysis (p = 0.215). Thirty-two percent of patients experienced a grade 3 treatment-related adverse event (TRAE). There were no grade 4 TRAEs and 7 patients experienced a grade 3 TRAE. Conclusion The combination of metformin, everolimus and exemestane was safe and had moderate clinical benefit in overweight and obese with patients metastatic, hormone receptor-positive, HER2-negative breast cancer.
KeywordsMetformin Everolimus Exemestane Obesity Metastatic breast cancer
This work was supported by a PROMISE grant from Susan G. Komen for the Cure (to FJE, SCJY and VV), the Breast Cancer Research Foundation (to FJE), the National Institutes of Health through MD Anderson’s Cancer Center Support Grant (NCI P30 CA016672). Dr. Yam is supported by the Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, the Susan Papizan Dolan Fellowship in Breast Oncology, and the 2018 Gianni Bonadonna Breast Cancer Research Fellowship. Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the sponsors. The authors thank Jeanie F. Woodruff, BS. ELS, for editorial support.
This work was supported by a PROMISE grant from Susan G. Komen for the Cure (to FJE, SCJY and VV), the Breast Cancer Research Foundation (to FJE), the National Institutes of Health through MD Anderson’s Cancer Center Support Grant (NCI P30 CA016672). Dr. Yam is supported by the Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, the Susan Papizan Dolan Fellowship in Breast Oncology, and the 2018 Gianni Bonadonna Breast Cancer Research Fellowship. Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the sponsors.
Compliance with ethical standards
Conflict of interest
FJE has received honoraria from Novartis and Pfizer for consultancy. MCM has received honoraria for serving on the advisory boards of Roche and Pfizer and has received institutional research funding from Novartis. SCJY has received research funding and grant support from Bristol-Myers Squibb and DepoMed. GNH was the principal investigator of the BOLERO-2 trial and received research funding from Norvatis for conducting the trial and honoraria for chairing the protocol steering committee. VV has received honoraria from Novartis for consultancy. All other authors declare no relevant potential conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
Informed consent was obtained from all individual participants included in the study.
- 1.Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, Ochs-Balcom HM, Thomson CA, Caan BJ, Tinker LF, Urrutia RP, Knudtson J, Anderson GL (2015) Overweight, obesity, and postmenopausal invasive breast Cancer risk: a secondary analysis of the Women's Health Initiative randomized clinical trials. JAMA Oncol 1(5):611–621. https://doi.org/10.1001/jamaoncol.2015.1546 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B (2005) Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol 229(1–2):161–173. https://doi.org/10.1016/j.mce.2004.08.002 CrossRefPubMedGoogle Scholar
- 9.Bernard L, Legay C, Adriaenssens E, Mougel A, Ricort JM (2006) Estradiol regulates the insulin-like growth factor-I (IGF-I) signalling pathway: a crucial role of phosphatidylinositol 3-kinase (PI 3-kinase) in estrogens requirement for growth of MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun 350(4):916–921. https://doi.org/10.1016/j.bbrc.2006.09.116 CrossRefPubMedGoogle Scholar
- 10.Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, Chen J, Gully C, Carlock C, Qi Y, Zhang Y, Wu Y, Esteva FJ, Luo Y, McKeehan WL, Ensor J, Hortobagyi GN, Pusztai L, Fraser Symmans W, Lee MH, Yeung SC (2014) Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. J Natl Cancer Inst 106(7). https://doi.org/10.1093/jnci/dju158
- 13.Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA Jr, Fumagalli D, Sarp S, Wolff AC, Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, Gralow J, Keane M, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E (2017) Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast Cancer: analysis from the ALTTO phase III randomized trial. J Clin Oncol 35(13):1421–1429. https://doi.org/10.1200/JCO.2016.69.7722 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297–3302. https://doi.org/10.1200/JCO.2009.19.6410 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529. https://doi.org/10.1056/NEJMoa1109653 CrossRefGoogle Scholar
- 16.Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC (2013) Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol 71(1):63–72. https://doi.org/10.1007/s00280-012-1977-9 CrossRefPubMedGoogle Scholar
- 17.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefGoogle Scholar
- 18.Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA 3rd, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger. Ann Oncol 25(12):2357–2362. https://doi.org/10.1093/annonc/mdu456 CrossRefPubMedPubMedCentralGoogle Scholar